BioMedNewsBreaks

TuesdayOct 13, 2026 9:50 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Expands Florida Healthcare Network With New PharmcoRx Pharmacy in Jacksonville

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology solutions, announced the opening of a new PharmcoRx community pharmacy in Jacksonville, Florida, expanding its healthcare operations in the state. Located across from HCA Florida Memorial Hospital, the new facility offers prescription fulfillment, medication management, same-day delivery, specialty pharmacy services and patient support. The location also provides higher-margin contracted services for healthcare providers and institutions, including participants in the federal 340B drug pricing program, long-term care facilities and government agencies. PharmcoRx currently operates a network of six retail pharmacies across Florida. The expansion supports NextPlat's…

Continue Reading

TuesdayOct 13, 2026 9:10 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The in vivo study demonstrated significant tumor regression in a breast cancer model following a single 3 mg/kg dose, with no observed decrease in body weight. The results also showed that both BiTAC-ADC components were required to produce the intended tumor-specific response. Additional in vitro studies demonstrated the platform's ability to distinguish cancer cells from healthy cells, prevent the release of active…

Continue Reading

MondayOct 12, 2026 1:55 pm

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports Strong Surgeon Interest in GelrinC at International Cartilage Summit

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced strong interest and engagement from orthopedic surgeons, physicians and cartilage repair specialists at the 8th International Cartilage Regeneration & Joint Preservation Society ("ICRS") Summit, held Oct. 8-10 in Porto, Portugal. Discussions focused on GelrinC(R), the company's CE Mark-approved, cell-free hydrogel implant designed to regenerate damaged knee cartilage through a single procedure lasting approximately 10 minutes. In a Phase II study, GelrinC demonstrated approximately 100% greater improvement in overall Knee Injury and Osteoarthritis Outcome Score ("KOOS") scores compared with historical microfracture controls at two years,…

Continue Reading

MondayOct 12, 2026 9:20 am

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) to Present at 2026 ThinkEquity Conference on Oct. 15

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced that CEO and Executive Chairman Ehud Geller will present at the 2026 ThinkEquity Conference on Oct. 15, 2026, at 10 a.m. at the Mandarin Oriental Hotel in New York City. Geller will provide an overview of the company’s GelrinC(R) technology, recent clinical developments, progress in its ongoing U.S. Food and Drug Administration ("FDA") pivotal Phase III trial and preparations for commercialization in Europe, where GelrinC has received CE Mark approval. Geller and Chief Financial Officer Ori Gon will also be available for one-on-one meetings…

Continue Reading

FridayOct 09, 2026 12:53 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Builds Scalable Business Through Vertical Integration, Dual-Market Strategy

Earth Science Tech (OTC: ETST) is building a scalable, self-sustaining healthcare business through strategic acquisitions, end-to-end vertical integration, and a dual B2B and B2C revenue model. Its portfolio of pharmacies, telehealth platforms, and pharmaceutical distribution businesses connects patient consultations, clinical support, compounded medication production, and fulfillment while helping streamline operations and control supply costs. With its compounding pharmacies licensed across 34 U.S. jurisdictions, the company is expanding its reach while generating consumer-facing revenue and higher-margin business-to-business income from infrastructure and compounding services provided to third-party healthcare providers. As ETST enters fiscal 2027, management plans to expand the geographic footprint of its…

Continue Reading

ThursdayOct 08, 2026 2:35 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Seeks to Redefine Knee Cartilage Repair with Resorbable Hydrogel Technology

Regentis Biomaterials (NYSE American: RGNT) is developing GelrinC, an acellular hydrogel implant designed to shift knee cartilage treatment from symptom management toward early structural repair. Unlike microfracture, which can produce less-durable fibrocartilage, GelrinC is engineered to gradually resorb as surrounding cells regenerate hyaline-like cartilage, while avoiding cell harvesting and a second surgery. In a Phase II study, the company reported roughly 100% greater KOOS improvement versus microfracture at 24 months, along with a mean MOCART score of 88.8/100 indicating strong structural repair. With CE Mark approval in Europe, a pivotal U.S. trial targeting completion around year-end 2026, and longer-term development programs…

Continue Reading

WednesdayOct 07, 2026 10:40 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

VERAXA Biotech (NASDAQ: VRXA) , a developer of next-generation antibody-based cancer therapies, provided an update on its strategy to implement U.S. Food and Drug Administration “FDA”-aligned New Approach Methodologies “NAMs” across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines and significantly reduce animal testing. VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates and bispecific antibody-drug conjugates. VERAXA said its lead BiTAC-TCE and bsADC candidates were also evaluated using an ex vivo panel of 10 low-passage patient-derived…

Continue Reading

TuesdayOct 06, 2026 11:40 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) entered into a Study Start-Up Agreement (“SUA”) with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302 (“Lucid-MS”) for multiple sclerosis (“MS”). The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial. Thermo Fisher will support study start-up and related clinical research services through its PPD(TM) Clinical Research Business. Quantum BioPharma said the randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints. Lucid-MS is an…

Continue Reading

TuesdayOct 06, 2026 9:00 am

BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Data for ENV-105 in Prostate Cancer

Kairos Pharma (NYSE American: KAPA) announced positive interim efficacy data from its ongoing Phase 2 trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer. The analysis showed a statistically significant difference in progression-free survival, with median PFS of 17.7 months for patients receiving ENV-105 plus apalutamide compared with two months for those receiving apalutamide alone (P=0.0008). Kairos Pharma has modified the Phase 2 protocol to enroll patients earlier in disease progression, with patients who experience a PSA increase following upfront treatment with an androgen signaling inhibitor to be randomized to enzalutamide alone or enzalutamide in…

Continue Reading

MondayOct 05, 2026 12:03 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Opens BIO REBOOT Registration, Announces PDAOAI Presentations at Drug Discovery 2026 

Oncotelic Therapeutics (OTCQB: OTLC), together with its wholly owned subsidiary Pet2DAO, Inc., announced that its PDAOAI artificial intelligence-powered drug discovery platform is inviting scientists, AI developers and biotech founders to participate in BIO REBOOT. Participants can bring research questions, technical expertise and drug discovery ideas to the PDAOAI community, with selected projects potentially considered for startup funding and Oncotelic support covering validation, formulation, regulatory planning and clinical development. Oncotelic also announced two PDAOAI keynote presentations at the 10th International Conference on Drug Discovery & Lead Optimization, taking place Oct. 7-9, 2026, in Burlingame, California. Chief Business Officer Saran Saund will…

Continue Reading